Article
The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
Cancer chemotherapy and pharmacology - 1 Mar 2013
Opdam F L, Dezentje V O, den Hartigh J, Modak A S, Vree R, Batman E, Smorenburg C H, Nortier J W R, Gelderblom H, Guchelaar H-J
Abstract excerpt
PURPOSE: Adjuvant therapy with tamoxifen significantly reduces breast cancer recurrence and mortality in estrogen receptor positive disease. CYP2D6 is the main enzyme involved in the activation of the prodrug tamoxifen into the anti-estrogen endoxifen. Endoxifen is thought to be a main determinant for clinical efficacy in breast cancer patients using tamoxifen. As the large interindividual variation in endoxifen...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.